Lettieri Christina K, Appel Nicole, Labban Nicole, Lussier Danielle M, Blattman Joseph N, Hingorani Pooja
Children's Hospital & Medical Center, Omaha, NE 68198, USA.
School of Life Sciences, Arizona State University, Tempe, AZ 85281, USA.
Immunotherapy. 2016 Oct;8(10):1233-44. doi: 10.2217/imt-2016-0048.
Survival outcomes for osteosarcoma have plateaued since the 1980s, and patients with relapsed or refractory disease have a particularly dismal outcome. Treatment options for these patients are limited primarily due to the paucity of effective therapeutics. Immune therapies such as tumor vaccines and traditional antigen-targeted monoclonal antibodies have had limited success in solid tumors. The recent discovery of novel immune checkpoint blockade strategies and their success in adult cancers has revitalized the use of immunotherapy strategies for the treatment of solid tumors. This paper summarizes existing data supporting the use of immune therapies in osteosarcoma and the progress of this class of drugs in osteosarcoma therapy.
自20世纪80年代以来，骨肉瘤的生存结果一直停滞不前，复发或难治性疾病患者的预后尤其不佳。这些患者的治疗选择主要由于有效治疗方法的匮乏而受到限制。肿瘤疫苗和传统抗原靶向单克隆抗体等免疫疗法在实体瘤中的成功有限。新型免疫检查点阻断策略的最新发现及其在成人癌症中的成功，使免疫治疗策略在实体瘤治疗中的应用得以复兴。本文总结了支持在骨肉瘤中使用免疫疗法的现有数据以及这类药物在骨肉瘤治疗中的进展。
